Počet záznamů: 1
Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
- 1.
SYSNO ASEP 0446855 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer Tvůrce(i) Tomasetti, M. (IT)
Santarelli, L. (IT)
Alleva, R. (IT)
Dong, L.F. (AU)
Neužil, Jiří (BTO-N) RIDZdroj.dok. Current Medicinal Chemistry. - : Bentham Science Publishers - ISSN 0929-8673
Roč. 22, č. 5 (2015), s. 552-568Poč.str. 17 s. Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova Apoptosis ; autophagy ; redox-active agents Vědní obor RIV EB - Genetika a molekulární biologie CEP ED1.1.00/02.0109 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Institucionální podpora BTO-N - RVO:86652036 UT WOS 000349387200002 Anotace Tumours exhibit higher basal levels of reactive oxygen species (ROS) and altered redox environment compared to normal cells. Excessive level of ROS can be toxic to these cells, thus they become more vulnerable to damage by further ROS insults induced by pharmacological agents. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Therefore, abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. Many redox-modulating agents have been developed. The redox-active system epitomised by ascorbate-driven quinone redox cycling, and the group of redox-silent vitamin E analogues represented by alpha-tocopheryl succinate have been shown to induce selective cancer cell death in different types of cancer. These compounds synergistically act by destabilising organelles like mitochondria, unleashing their apoptogenic potential, which results in efficient death of malignant cells and suppression of tumour growth. Consistent with this notion, clinical trials that aim to examine the therapeutic performance of novel redox-modulating drugs in cancer patients are currently under way Pracoviště Biotechnologický ústav Kontakt Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Rok sběru 2016
Počet záznamů: 1